Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“A pioneer in APS testing, Prof. Pier Luigi Meroni delivered a powerful message at ISTH 2026 in Paris yesterday: what do we really target with our aPL assays?
His update on harmonizing ELISA and non‑ELISA antiphospholipid antibody tests with new commutable reference material for anti‑β2GPI and aCL IgG showed that standardization of units is possible—but that variability from assay design and antibody heterogeneity remains.
For me, the key takeaway was a clear shift from ‘any aPL positive’ towards biologically meaningful β2GPI‑dependent specificities and domain reactivity, which should drive future APS risk stratification, classification, and guidelines.
But how ready are our routine laboratories to embrace this more targeted, domain‑focused approach to APS testing?”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies